enGene Holdings Inc. (ENGN)
enGene Holdings Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Montreal, QC, CA. The stock last traded at $1.82, up 4.00% on the session, giving a market capitalisation of $121.9M. On trailing twelve-month figures it carries a trailing P/E of -1.38, a net margin of 0.0%. Its beta of -0.28 implies it has historically moved less than the broad market.
Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.
enGene Holdings Inc. is most often compared with the following Healthcare names: